Novartis’ $2 Million Gene Therapy Zolgensma Shows ‘Remarkable’ Results and Offers Hope for Children with SMA
XTalks
JUNE 8, 2021
With a price tag of over $2.5 The researchers conducted a long-term follow-up study of the START trial that included patients who completed phase I of the study. Given that SMA is a rare condition, a specialized drug had to be created for it, which required intense research and the right expertise.
Let's personalize your content